| 18.09 -0.26 (-1.42%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 23.06  |
1-year : | 24.52 |
| Resists | First : | 19.74 |
Second : | 21 |
| Pivot price | 19.62 |
|||
| Supports | First : | 17.7 |
Second : | 14.73 |
| MAs | MA(5) : | 18.65 |
MA(20) : | 19.69 |
| MA(100) : | 20.22 |
MA(250) : | 19.91  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 13.7 |
| RSI | RSI(14): 35.3 |
|||
| 52-week | High : | 25.59 | Low : | 12.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SNDX ] has closed above bottom band by 5.5%. Bollinger Bands are 10.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.24 - 18.34 | 18.34 - 18.42 |
| Low: | 17.4 - 17.54 | 17.54 - 17.66 |
| Close: | 17.88 - 18.09 | 18.09 - 18.27 |
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Tue, 15 Sep 2026
SNDX: Key phase II readouts and expanding maintenance therapy drive growth and pipeline momentum - TradingView
Tue, 15 Sep 2026
SNDX: Strong commercial growth and pivotal clinical catalysts set the stage for major pipeline advances - TradingView
Mon, 14 Sep 2026
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sun, 13 Sep 2026
WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Fri, 11 Sep 2026
Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Fri, 04 Sep 2026
Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 126.2 (%) |
| Shares Short | 22,900 (K) |
| Shares Short P.Month | 20,820 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.17 |
| Profit Margin | -87.6 % |
| Operating Margin | -55 % |
| Return on Assets (ttm) | -18.7 % |
| Return on Equity (ttm) | -256 % |
| Qtrly Rev. Growth | 91.8 % |
| Gross Profit (p.s.) | -0.23 |
| Sales Per Share | 2.82 |
| EBITDA (p.s.) | -2.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -221 (M) |
| Levered Free Cash Flow | -150 (M) |
| PE Ratio | -7.21 |
| PEG Ratio | 0 |
| Price to Book value | 106.41 |
| Price to Sales | 6.4 |
| Price to Cash Flow | -7.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|